Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
BOSTON and MENLO PARK, Calif., Oct. 10, 2013 /PRNewswire/ -- Auxogyn, Inc., a leader in reproductive health that provides novel scientific and clinically validated solutions to in vitro fertilization (IVF) clinicians and their patients, today announced upcoming presentations of the latest research data on its Eeva™ Technology the American Society for Reproductive Medicine (ASRM) Annual Meeting. The meeting is being held October 12-17 in Boston.
"We are pleased that our Eeva Technology and resulting clinical data will be so prominently represented at the upcoming ASRM Annual Meeting," stated Lissa Goldenstein, President and CEO of Auxogyn. "Auxogyn remains committed to supporting the pursuit of clinical research with the goal of improving clinical care and outcomes for women undergoing IVF."
Notable data from Auxogyn at ASRM 2013 include:
Please note that all abstracts are embargoed until the date and time of publication.
Auxogyn is also sponsoring a seminar covering the latest information on embryo assessment:
Full session details and data presentation listings for the 2013 meeting can be found on the ASRM website at www.asrm.org/IFFS-ASRM2013/.
Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information visit auxogyn.com and follow us on Twitter @Auxogyn.
About the Eeva™ Test
The Eeva Test provides IVF clinicians with information about the embryo's development potential. Eeva proprietary software automatically analyzes embryo development against scientifically validated cell-division parameters conceived by researchers at Stanford University in the US. With results from the Eeva Test, IVF teams will have morphological assessment and objective information to aid their embryo selection decisions. The Eeva Test was evaluated in a prospective, multi-center, 160-patient prospective multi-center trial with ~1,800 embryos. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.
The Eeva Test is currently CE Marked and available for use in the EU and authorized by Health Canada for sale in Canada. The FDA submission is pending and Eeva is not available for sale in the United States. For a full list of clinics in the EU offering the Eeva Test please visit www.eevaivf.com or follow us on Twitter @EevaIVF.
©2012 PR Newswire. All Rights Reserved.